MX2015005937A - Metodo de tratamiento de la agresion. - Google Patents

Metodo de tratamiento de la agresion.

Info

Publication number
MX2015005937A
MX2015005937A MX2015005937A MX2015005937A MX2015005937A MX 2015005937 A MX2015005937 A MX 2015005937A MX 2015005937 A MX2015005937 A MX 2015005937A MX 2015005937 A MX2015005937 A MX 2015005937A MX 2015005937 A MX2015005937 A MX 2015005937A
Authority
MX
Mexico
Prior art keywords
aggression
treatment
molindone
dose
human subject
Prior art date
Application number
MX2015005937A
Other languages
English (en)
Spanish (es)
Inventor
Ph D Adam Kenneth Hamm
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of MX2015005937A publication Critical patent/MX2015005937A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015005937A 2012-11-13 2013-11-13 Metodo de tratamiento de la agresion. MX2015005937A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725883P 2012-11-13 2012-11-13
US201261727570P 2012-11-16 2012-11-16
PCT/US2013/069863 WO2014078394A1 (en) 2012-11-13 2013-11-13 Method of treatment of aggression

Publications (1)

Publication Number Publication Date
MX2015005937A true MX2015005937A (es) 2015-09-08

Family

ID=49681174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005937A MX2015005937A (es) 2012-11-13 2013-11-13 Metodo de tratamiento de la agresion.

Country Status (7)

Country Link
US (1) US20140135326A1 (enExample)
EP (2) EP3524251A1 (enExample)
JP (1) JP2015536999A (enExample)
AU (2) AU2013344920A1 (enExample)
CA (1) CA2888725A1 (enExample)
MX (1) MX2015005937A (enExample)
WO (1) WO2014078394A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009335709A1 (en) 2008-12-19 2011-07-14 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
CA3022339A1 (en) * 2016-04-29 2017-11-02 Supernus Pharmaceuticals, Inc. Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
WO2004069339A1 (en) * 2003-01-29 2004-08-19 Psychogenics Inc. Treatment for attention-deficit hyperactivity disorder
AU2009335709A1 (en) 2008-12-19 2011-07-14 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
AU2011235222B2 (en) * 2010-03-31 2014-09-25 Supernus Pharmaceuticals Inc. Stabilized formulations of CNS compounds

Also Published As

Publication number Publication date
AU2013344920A1 (en) 2015-04-30
US20140135326A1 (en) 2014-05-15
JP2015536999A (ja) 2015-12-24
EP3524251A1 (en) 2019-08-14
AU2018202636A1 (en) 2018-05-10
WO2014078394A1 (en) 2014-05-22
CA2888725A1 (en) 2014-05-22
EP2919787A1 (en) 2015-09-23

Similar Documents

Publication Publication Date Title
MY172578A (en) Oral dosing of glp-1 compounds
PH12014501844B1 (en) Peptidomimetic macrocycles
PH12015500196A1 (en) Methods of treating a tauopathy
MX365418B (es) Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
PH12015500276A1 (en) Treatment of immune-related and inflammatory diseases
GB2508521A (en) Efficient and scalable cyclic redundancy check using galois-field arithmetic
UA117556C2 (uk) Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату
EA201590359A1 (ru) Лечение ревматоидного артрита
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
MX2015006407A (es) Procedimiento de preparacion de albumina humana con nivel de oxigeno disuelto reducido.
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
MX2022001880A (es) Metodos para mejorar la salud del sistema respiratorio y aumentar la concentracion del ion hipotiocianato en los pulmones de los vertebrados.
MX2021003826A (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12014502259A1 (en) Association of beta-glucans and arabinoxylans
MX2015005937A (es) Metodo de tratamiento de la agresion.
GB2509663A (en) Treatment of adrenal insufficiency
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.